The company behind the experimental coronavirus treatment remdesivir has signed non-exclusive licensing deals with five drugmakers based in India and Pakistan to make and sell the antiviral medicine in 127 countries.
Gilead Sciences said the agreements cover almost all of the world’s low-income and lower-middle income countries, including Afghanistan, India, North Korea, Pakistan and South Africa.
The pacts also include several upper-middle and high-income nations.
This month both the US and Japan authorised remdesivir as a treatment for Covid-19 patients.
Many other pharmaceutical companies are racing to develop a treatment or vaccine to combat the pandemic.